Regulation of neurotrophic factors by antipsychotic drug treatments in animals and schizophrenic patients
| Treatment | Factor/Region | Effect | Reference |
|---|---|---|---|
| Atypical | |||
| Clozapine (10 mg/kg, 28 days) | BDNF/HP | Decreased | Lipska et al., 2001 |
| Clozapine (20 mg/kg, 19 days) | BDNF/HP | No Effect | Chlan-Fourney et al., 2002 |
| Clozapine (27 mg/kg, 28 days) | BDNF/HP | Decreased | Bai et al., 2003 |
| Olanzapine (2.7 mg/kg, 28 days) | BDNF/HP | Increased | Bai et al., 2003 |
| Olanzapine (15 mg/kg, 30 days) | BDNF/HP | Decreased | Angelucci et al., 2005 |
| Olanzapine (10 mg/kg, 45 days) | BDNF/HP | No effect | Parikh et al., 2004a |
| Risperidone (2.3 mg/100g food, 19 days) | BDNF/HP, FrCtx | Decreased | Angelucci et al., 2000b |
| Risperidone (1 mg/kg, 19 days) | BDNF/HP | No effect | Chlan-Fourney et al., 2002 |
| Risperidone (4 mg/kg, 19 days) | BDNF/HP | Decreased | Chlan-Fourney et al., 2002 |
| Olanzapine (15 mg/kg) | NGF/HP, OcCtx | Increased | Angelucci et al., 2005 |
| Risperidone (2.3 mg/100g food, 19 days) | NGF/HP, Striatum | Decreased | Angelucci et al., 2000a |
| Clozapine (10 mg/kg, 21 days) | FGF2/PfrCtx, Striatum | Increased | Riva et al., 1999; Maragnoli et al., 2004 |
| Typical | |||
| Haloperidol (1.15 mg/100g food, 19 days) | BDNF/HP, FrCtx | Decreased | Angelucci et al., 2000b |
| Haloperidol (1 mg/kg, 28 days) | BDNF/HP | Decreased | Lipska et al., 2001 |
| Haloperidol (2 mg/kg, 21 days) | BDNF/HP, FrCtx | Decreased | Nibuya et al., 1995 |
| Haloperidol (1 mg/kg, 28 days) | BDNF/HP | Decreased | Bai et al., 2003 |
| Haloperidol (1 mg/kg, 19 days) | BDNF/HP | Decreased | Chlan-Fourney et al., 2002 |
| Haloperidol (2 mg/kg) | BDNF/HP | Decreased | Parikh et al., 2004a |
| Haloperidol (1 mg/kg, 3 days) | BDNF/Amy, Ctx | Decreased | Meredith et al., 2004 |
| Ritanserin (2 mg/kg, 19 days) | BDNF/HP (CA1) | Decreased | Chlan-Fourney et al., 2002 |
| Eticlopride (3 mg/kg, 3 days) | BDNF/Amy, Ctx | Decreased | Meredith et al., 2004 |
| Haloperidol (1.15 mg/100g food, 19 days) | NGF/HP, striatum | Decreased | Angelucci et al., 2000a |
| Haloperidol (1 mg/kg, 21 days) | FGF2/striatum | No effect | Riva et al., 1999 |
| Schizophrenia models | |||
| Ibotinic acid lesion | BDNF/HP, PfrCtx | Decreased | Lipska et al., 2001; Ashe et al., 2002 |
| MK-801 | BDNF/HP | Decreased | Fumagalli et al., 2003b |
| MK-801 + quetiapine | BDNF/HP | Normalized | Fumagalli et al., 2003b |
| MK-801 + haloperidol | BDNF/HP | Decreased | Fumagalli et al., 2003b |
| Stress | BDNF/HP | Decreased | Smith et al. 1995; Luo et al, 2004 |
| Stress + olanzapine | BDNF/HP | Increased | Luo et al., 2004 |
| Postmortem | |||
| Schizophrenic | BDNF/Ctx | Decreased | Durany et al., 2001 |
| Schizophrenic | BDNF/PfrCtx | Decreased | Weickert et al., 2003, 2005 |
| Schizophrenic | BDNF/Serum | Decreased | Toyooka et al., 2002 |
| Schizophrenic | BDNF/Serum | No effect | Shimizu et al., 2003 |
| Schizophrenic | BDNF/Serum | Decreased | Tan et al., 2005 |
HP, hippocampus; OcCtx, occipital cortex; FrCtx, frontal cortex; Amy, amygdala; CTx, cortex; PFRCtx, prefrontal cortex